scispace - formally typeset
K

Klaus Seppi

Researcher at Innsbruck Medical University

Publications -  366
Citations -  25650

Klaus Seppi is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Parkinsonism & Medicine. The author has an hindex of 74, co-authored 317 publications receiving 20534 citations. Previous affiliations of Klaus Seppi include University of Innsbruck.

Papers
More filters
Journal ArticleDOI

Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy.

TL;DR: The aim of this study was to identify the monoamine transporter distribution pattern in patients with the cerebellar variant of MSA (MSA‐C) and investigate its availability in a small cohort of patients with sporadic adult‐onset ataxia (SAOA).
Journal ArticleDOI

Effects of self-administered cannabidiol in a patient with multiple system atrophy.

TL;DR: The case of a 56-year-old male Caucasian patient diagnosed with probable Parkinson variant MSA (MSA-P), who took CBD on his own initiative, is reported, which suggested that CBD reduces psychosis and symptoms of REM sleep behavior disorder in PD.
Journal ArticleDOI

Automated segmentation of deep brain nuclei using convolutional neural networks and susceptibility weighted imaging

TL;DR: In this article, state-of-the-art CNN architectures were evaluated for the labeling of deep brain nuclei from susceptibility weighted imaging (SWI) images, and a multi-atlas segmentation model was included to provide a comparison not based on CNN.
Journal ArticleDOI

Intensive care management in very old adults: two cases with clostridium tetani infection.

TL;DR: Two cases with Clostridium tetani infection are reported, the complicated hospital course described, and the importance of preventive vaccination strategies discussed.
Journal ArticleDOI

Antipsychotikainduzierte tardive Syndrome

TL;DR: This manuscript summarizes the current evidence with respect to the phenomenology, course, prevention and treatment of tardive syndromes and discontinuing the antipsychotic, if possible, albeit not backed up by unequivocal evidence, is still the main recommendation.